JL Blum

408 total citations
25 papers, 202 citations indexed

About

JL Blum is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, JL Blum has authored 25 papers receiving a total of 202 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Genetics. Recurrent topics in JL Blum's work include Advanced Breast Cancer Therapies (11 papers), Cancer Treatment and Pharmacology (10 papers) and Breast Cancer Treatment Studies (6 papers). JL Blum is often cited by papers focused on Advanced Breast Cancer Therapies (11 papers), Cancer Treatment and Pharmacology (10 papers) and Breast Cancer Treatment Studies (6 papers). JL Blum collaborates with scholars based in United States, Spain and France. JL Blum's co-authors include Joyce O’Shaughnessy, Robert Mennel, John D. Hainsworth, Stephen E. Jones, Filippo Greco, Michael Danso, Paul Richards, Miguel Martín, Rinat Yerushalmi and Jennifer K. Litton and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

JL Blum

25 papers receiving 191 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
JL Blum United States	8	181	80	53	47	33	25	202
Fernanda Mosele France	5	72 0.4×	79 1.0×	53 1.0×	45 1.0×	12 0.4×	8	131
Kathleen Klein Oros Canada	6	63 0.3×	67 0.8×	59 1.1×	111 2.4×	67 2.0×	8	195
Claudette Falato Spain	10	161 0.9×	107 1.3×	78 1.5×	78 1.7×	41 1.2×	20	261
Brooke Daniel United States	7	170 0.9×	58 0.7×	69 1.3×	31 0.7×	7 0.2×	17	196
Ruth M. O'Regan United States	3	100 0.6×	92 1.1×	40 0.8×	35 0.7×	29 0.9×	4	158
M. Kandel Germany	5	94 0.5×	75 0.9×	32 0.6×	31 0.7×	43 1.3×	5	184
Jasmina Bojadzieva United States	6	127 0.7×	73 0.9×	21 0.4×	87 1.9×	75 2.3×	9	192
Lori Marini United States	4	127 0.7×	71 0.9×	95 1.8×	58 1.2×	20 0.6×	10	193
Tressa Hood United States	8	71 0.4×	43 0.5×	32 0.6×	37 0.8×	12 0.4×	20	133
Vinay Gudena United States	6	102 0.6×	31 0.4×	40 0.8×	53 1.1×	12 0.4×	18	181

Countries citing papers authored by JL Blum

Since Specialization

Citations

This map shows the geographic impact of JL Blum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JL Blum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JL Blum more than expected).

Fields of papers citing papers by JL Blum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JL Blum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JL Blum. The network helps show where JL Blum may publish in the future.

Co-authorship network of co-authors of JL Blum

This figure shows the co-authorship network connecting the top 25 collaborators of JL Blum. A scholar is included among the top collaborators of JL Blum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JL Blum. JL Blum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blum, JL, et al.. (2024). Combining reproductive endocrinology and ROC analysis to identify changes with sex, age, and pregnancy status in botos Inia geoffrensis. Endangered Species Research. 54. 409–426. 1 indexed citations

Martín, M., H. S. Rugo, Sara A. Hurvitz, et al.. (2021). 272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC). Annals of Oncology. 32. S481–S481. 1 indexed citations

Litton, Jennifer K., HS Rugo, Johannes Ettl, et al.. (2018). Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. Cancer Research. 78(4_Supplement). GS6–7. 40 indexed citations

Tripathy, Debu, Aditya Bardia, JL Blum, et al.. (2018). Abstract OT3-05-03: POLARIS: Palbociclib (P) in hormone receptor-positive (HR+) advanced breast cancer: A prospective multicenter noninterventional study. Cancer Research. 78(4_Supplement). OT3–5. 2 indexed citations

Litton, JK, JL Blum, Y-H Im, et al.. (2016). Abstract OT1-03-16: EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer. Cancer Research. 76(4_Supplement). OT1–3. 2 indexed citations

Glück, Stefan, et al.. (2013). Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: Results of an exploratory analysis. The Breast. 22(6). 1087–1093. 6 indexed citations

Baselga, José, Serafín Morales, Ahmad Awada, et al.. (2013). Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer. Cancer Research. 73(24_Supplement). P2–16. 3 indexed citations

Blum, JL, et al.. (2011). PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.. Cancer Research. 71(24_Supplement). PD01–1. 14 indexed citations

Blum, JL, et al.. (2011). P5-19-08: Pooled Analysis of Individual Patient Data from Capecitabine Monotherapy Clinical Trials in Anthracycline-/Taxane-Pretreated Locally Advanced or Metastatic Breast Cancer (LA/MBC).. Cancer Research. 71(24_Supplement). P5–19. 1 indexed citations

10.

Blum, JL, Javier Cortés, HS Rugo, et al.. (2011). OT3-01-16: A Phase 2 Study of Ridaforolimus (RIDA) and Dalotuzumab (DALO) in Estrogen Receptor Positive (ER+) Breast Cancer.. Cancer Research. 71(24_Supplement). OT3–1. 1 indexed citations

11.

Sedlacek, Scot, S. Vukelja, Christopher Stokoe, et al.. (2011). P5-18-09: The Incidence of Febrile Neutropenia in the First Course of Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide with or without Pegfilgrastim.. Cancer Research. 71(24_Supplement). P5–18. 2 indexed citations

12.

Twelves, Chris, Danuta Z. Loesch, JL Blum, et al.. (2010). Abstract P6-14-18: Updated Survival Analysis of a Phase III Study (EMBRACE) of Eribulin Mesylate Versus Treatment of Physician's Choice in Subjects with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane. Cancer Research. 70(24_Supplement). P6–14. 5 indexed citations

13.

Blum, JL, et al.. (2010). Abstract P6-13-01: Impact of the Number of Prior Chemotherapy Regimens on Overall Survival (OS) among Subjects with Locally Recurrent or Metastatic Breast Cancer Treated with Eribulin Mesylate: Results from the Phase III EMBRACE Study. Cancer Research. 70(24_Supplement). P6–13. 3 indexed citations

14.

O’Shaughnessy, Joyce, JL Blum, C. Rocha, et al.. (2009). Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor.. Cancer Research. 69(2_Supplement). 2120–2120. 11 indexed citations

15.

Glück, Stefan, et al.. (2009). Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): An exploratory data analysis. Journal of Clinical Oncology. 27(15_suppl). 1024–1024. 6 indexed citations

16.

Danso, Michael, JL Blum, N. J. Robert, et al.. (2008). Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1075–1075. 27 indexed citations

17.

Blum, JL, Michael A. Savin, Gerald M. Edelman, et al.. (2004). Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. Journal of Clinical Oncology. 22(14_suppl). 543–543. 9 indexed citations

18.

Asmar, Lina, James Cantrell, S. Vukelja, et al.. (2004). A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study. Journal of Clinical Oncology. 22(14_suppl). 516–516. 2 indexed citations

19.

Hainsworth, John D., Stephen E. Jones, Robert Mennel, JL Blum, & Filippo Greco. (1996). Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial.. Journal of Clinical Oncology. 14(5). 1611–1616. 18 indexed citations

20.

Pilepich, M.V., Charles B. Anderson, Edward E. Etheredge, et al.. (1982). Graft irradiation in the treatment of acute rejection of renal transplants: A randomized study. International Journal of Radiation Oncology*Biology*Physics. 8(5). 823–827. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact